1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Neglected Tropical Diseases (NTDs) Funding (via The END Fund) is sponsored by The END Fund. The END Fund is a collaborative fund dedicated to ending six prevalent neglected tropical diseases, including schistosomiasis, by efficiently putting drug donations and private capital to work in support of country-led NTD programs that are innovative, integrated, cost-effective, and sustainable.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Neglected Tropical Diseases (NTDs) Funding (via The END Fund) is funded by The END Fund. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
HHS has obligated roughly half a percent of the FY2026 Teen Pregnancy Prevention appropriation with days left before September 30. Here is the full timeline, the replacement NOFO that closed in July, the August court ruling, and what grantees should be doing right now.
Read articleNIH released a draft policy on August 27, 2026 that would require every NIH-supported clinical study to offer participants a plain-language summary of results — clinical trials within one year of completion, all other clinical research by the end of the funding period. It covers observational and behavioral research that ClinicalTrials.gov never touched. Here is the scope, the four requirements nobody has budgeted for, and what to say before the October 26 deadline.
Read articleWith Forms J in FY2027, NIH will no longer accept letters of support — the boilerplate endorsements applicants have padded proposals with for decades. Notice NOT-OD-26-094 replaces them with letters of collaboration, aligning NIH with NSF. Here is exactly what changes, what a compliant letter must now contain, who can no longer write one, and how this fits the broader re-engineering of the NIH application package.
Read article